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Specificity constitutes a component of validity for a screening test. The number of false-positive (FP) results has been regarded as one
of major shortcomings in prostate cancer screening. We estimated the specificity of serum prostate-specific antigen (PSA)
determination in prostate cancer screening using data from a randomised, controlled screening trial conducted in Finland with 32000
men in the screening arm. We calculated the specificity as the proportion of men with negative findings (screen negatives, SN)
relative to those with negative and FP results (SN/(SNþFP)). A SN finding was defined as either PSAp4ngml
 1 or PSA 3.0–
3.9ngml
 1 combined with a negative ancillary test (digital rectal examination, DRE or free/total, F/T PSA ratio). False positives were
those with positive screening test followed by a negative diagnostic examination. Of the 30194 eligible men, 20794 (69%) attended
the first screening round and 1968 (9.5%) had a screen-positive finding. A total of 508 prostate cancers were detected at screening
(2.4%). Hence, the number of SN findings was 18825 and the number of FP results 1358. Specificity was estimated as 0.933 (18825
out of 20183) with 95% confidence interval (CI) 0.929–0.936. Specificity decreased with age. Digital rectal examination as ancillary
examination had similar or higher specificity than F/T PSA. In the second screening round, specificity was slightly lower (0.912, 95% CI
0.908–0.916). The specificity of PSA screening in the Finnish screening trial is acceptable. Further improvement in specificity could,
however, improve acceptability of screening and decrease screening costs.
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The validity of a screening test is the capability to discriminate
between those with and without disease, and can be measured by
sensitivity and specificity (Hakama, 1991). Ideally, a screening test
should be able to classify correctly both subjects with and without
the target disorder. In practice, the distributions of test values
between these two populations always overlap. Sensitivity indicates
the capacity to find persons with disease, whereas specificity is the
ability to identify those free of the target disorder. Sensitivity and
specificity are characteristics of the test that are independent of the
occurrence of the disease in the target population, but may depend
on disease characteristics. Specificity is inversely proportional to
the frequency of FP tests in those free of disease. In the context
of cancer screening, optimal specificity depends on how many
negative (unnecessary) biopsies one is willing to accept in order to
detect one case of cancer. Specificity of a screening test is an
indicator of the adverse effects of screening, including the cost and
inconvenience owing to the diagnostic examination. Specificity is a
characteristic of the test and an indicator of test performance used
in evaluation of screening methods, but not directly applicable in
decision making at the individual level.
Prostate cancer is one of the most common cancers among men
in the industrial countries (Parkin et al, 2002). Serum prostate-
specific antigen (PSA) was identified in the 1970s (Ablin et al,
1970; Li and Beling 1973) and later shown to be a marker of
prostate cancer (Wang et al, 1981). It has been adopted for case
finding among asymptomatic men, which has substantially
increased the detection and incidence of prostate cancer (Hankey
et al, 1999; Etzioni et al, 2002). Opportunistic screening with PSA
is widespread, but the evidence for its effectiveness in terms of
mortality reduction is still lacking (Auvinen et al, 2002). One of the
problems with PSA screening is the large proportion of FP results,
as PSA is an organ-specific, but not disease-specific marker
(Stenman et al, 2000). The main cause of elevated serum PSA
concentration is benign prostatic hyperplasia. A positive screening
test in the absence of disease leads to unnecessary biopsies and
constitutes an adverse effect of screening, which adds costs,
increases overdiagnosis and overtreatment and can affect accept-
ability of screening, that is, reduce participation at subsequent
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sscreening rounds. This is especially important in population
screening, where the proportion of those with disease is low.
The aim of the study was to estimate the specificity of the PSA
test in the Finnish prostate cancer screening trial.
MATERIALS AND METHODS
The Finnish prostate cancer screening trial is the largest centre of
the European Randomised Study of Prostate Cancer screening (de
Koning et al, 2002). It was started in 1996 in two metropolitan
regions, Helsinki and Tampere. The study population of 80458
men at ages 55–67 years was identified from the Population
Register Centre of Finland. Men who had denied the use of their
addresses were ineligible (approximately 1%), as well as men with
a previous prostate cancer (N¼161) and they were excluded from
the trial. During 1996–1999, 8000 men were annually randomly
allocated to the screening arm using a computer algorithm based
on random numbers and were invited for the first screening round.
The second screening round was carried out after a 4-year interval
between 2000 and 2003. The rest of the target population
comprised the control arm of the trial. Individuals in the control
arm were not contacted.
An invitation letter was sent to the men of the screening arm
with an information leaflet describing the trial, appended with a
brief questionnaire about urological symptoms, family history of
prostate cancer, previous PSA tests and an informed consent form
to be signed by the subject. This approach is called randomisation
before consent or Zelen-type randomisation (Zelen, 1979).
After an informed consent, a blood sample was drawn at the
local cancer society clinics in Helsinki and Tampere. Serum PSA
concentrations were analysed at the Central Laboratory of Helsinki
University Hospital by Hybritech Tandem-E for determination of
total PSA and Wallac AutoDelfia for free PSA.
Men with serum PSAX4ngml
 1 were referred to the local
hospital for diagnostic examinations, including three examinations
for all men: digital rectal examination (DRE), transrectal
ultrasound (TRUS) and prostate biopsy (compliance with biopsy
95%). Men with serum PSA concentration 3.0–3.9ngml
 1 were
referred for supplementary test: DRE during the first 3 years and
the proportion of free PSA (F/T-PSA) since 1999 with a cutoff
point of 0.16. Those with a positive ancillary test were also referred
to diagnostic work-up. Diagnosis of prostate cancer was based on
histological confirmation. The biopsy protocol consisted initially
of sextant biopsies, but the number of cores was increased to 10–
12 in 2002. A re-biopsy was carried out if either the PSA was above
10ngml
 1 or the initial histopathologic diagnosis was prostatic
intraepithelial neoplasia, atypical small acinar proliferation or
unconfirmed suspicion for carcinoma. Information on screen-
detected cases was obtained from the trial database and interval
cancers were identified from the population-based, nationwide
Finnish Cancer Registry (Teppo et al, 1994).
Specificity was defined as the proportion of the disease-free men
correctly classified as negative by the test (PSAo4.0mgml
 1,o r
PSA 3.0–3.9ngml
 1 with a positive ancillary test), among men
classified as disease-free during the screening episode (including
both SN men and those who were screen positive but had a negative
biopsy). Confidence interval (CI) for specificity was calculated
based on standard error for a proportion, s.e. (p)¼O(pq/n).
The study protocol was approved by the ethical committees in
each participating hospital. Permission to use the data of the
cancer registry was obtained from the Research and Development
Center for Welfare and Health (STAKES).
RESULTS
In the target population of 80458 men, 8000 men were randomly
allocated to the screening arm each year during the enrolment
period, 1996–1999. At the time of the invitation to the first
screening round, 30194 were eligible and invited. Of them, 20794
(69%) participated in the first screening round. A drop-out
analysis showed that young age and residence in Helsinki area
were associated with non-participation (mean ages 59.8 vs 60.2
years and 81% vs 72% resident in Helsinki region among non-
participants and participants). Of the participants, 18,825 had
serum PSA concentration below 3ngml
 1 or PSA 3.0–3.9ngml
 1
in combination with negative DRE or free/total ratio X0.16
(Table 1). Thus, the number of screen-positive men was 1968 and
prostate cancer was histologically confirmed in 508 subjects. The
histological finding was benign in 1358 men and 102 subjects
(5.2%) did not undergo biopsy.
Based on these observations, the specificity of the screening test
was estimated as (18825)/(18825þ1358) that is, 0.933 with 95%
CI 0.929–0.936 (Table 2). Men without biopsy were excluded from
this calculation. Specificity decreased with increasing age, from
0.97 at age 55 to 0.88 at 67 years.
Assuming a similar proportion of cancers and benign findings
among the 102 men who were not biopsied as among the screen-
positive men who underwent biopsy (102K(508/{508þ1,358})),
the number of cancers was estimated as 28 and number of men
with FP screening test as 74. Therefore, a corrected estimate of the
relative specificity of the PSA test was virtually identical to the
original: (18825)/(18825þ1432)¼0.929 (95% CI 0.926–0.933).
After the first 3 years of screening, DRE was replaced with F/T
PSA ratio as ancillary test among men with PSA 3.0–3.9ngml
 1.
The proportion of FP results among men with PSA in this range
was 7% with DRE (59 out of 794) and 16% with F/T PSA ratio
40.16 (44 out of 269). The overall number of SN findings during
the three initial years was 14149 and the number of FP findings
995 (7.0%). During the last year of the first screening round, the
corresponding figures were 4540 and 368 (8.1%). Hence, adoption
of the F/T PSA to replace DRE was associated with a nonsignificant
Table 1 Number of men by screening result and prostate cancer
diagnosis in the first screening round, Finnish prostate cancer screening trial
Prostate cancer diagnosis
Screening result Yes No Total
Positive 508
a 1358 1866
b
Negative 42
c 18783 18825
Total 550 20141 20691
b
aScreen-detected prostate cancer.
bA total of 102 screen-positive men failed to
undergo biopsy and were excluded.
cInterval cancer among screen-negative men.
Table 2 The frequency of TN and FP screening findings by age in the
first screening round of the Finnish prostate cancer screening trial
Age TN
a FP
b Specificity (95% CI)
c
55 6153 214 0.966 (0.962–0.971)
59 5137 279 0.948 (0.943–0.954)
63 4146 409 0.910 (0.902–0.919)
67 3389 456 0.881 (0.871–0.892)
Total 18825 1358 0.933 (0.929–0.936)
Abbreviations: CI¼confidence interval; FP¼false positive; TN¼true negative.
aTN:
No. of men with negative screening result (serum PSAo3.0ngml
 1 or PSA 3.0–
3.9ngml
 1 with a negative ancillary examination (benign finding at digital rectal
examination or free/total PSA ratioX0.16)).
bFP: No. of men with positive screening
result (serum PSAo4.0ngml
 1 or PSA 3.0–3.9ngml
 1 with a positive ancillary
examination (suspicious finding at digital rectal examination or free/total PSA
ratioo0.16)) minus number of screen-detected cancers. Note: men refusing biopsy
(N¼102) excluded.
cSpecificity: TN/(TN+FP).
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sdecrease in specificity of the screening programme, 0.934 (0.930–
0.938) vs 0.925 (0.917–0.932) in the first screening round.
Specificity in the second round was slightly lower compared
with the first round (Table 3). A total of 18612 men were screened
and 2303 screen-positive subjects referred to biopsy. Of them, 2156
were biopsied within the study (at the screening centres) and 583
cancers (3.1%) detected. Overall, specificity was 0.912 (95% CI
0.908–0.916, Table 4). Correction for missing biopsy results did
not materially affect the estimate (corrected specificity 0.910, 95%
CI 0.906–0.914). In men who attended screening for the first time
(i.e., were non-participants in the first round), specificity was 0.903
(95% CI 0.891–0.914), with a corrected estimate of 0.911 (0.900–
0.921). Similar to the first screening round, specificity decreased
with age. However, no obvious difference in specificity was found
within age group, that is, when comparing men at the same age in
the first vs second round. Specificity in the two screening rounds
remained comparable (0.917 and 0.922) after restricting the
analysis to the three age groups targeted in both rounds (59, 63
and 67 years, Figure 1). This suggests that the decrease in
sensitivity between the screening rounds was due to the older age
structure alone.
Some alternative screening algorithms can also be evaluated,
based on number of screen-positive findings. Had a cutoff limit of
3ngml
 1 been used, the number of test-positive men would have
been increased from 1980 (9.5%) to 2762 (13.3%) in the first
screening round. For the second screening round, the number of
screen-positive tests with a cutoff level of 3ngml
 1 would have
increased from 2303 to 3401 compared with the current protocol
(12.3% vs 18.3% screen positive).
Age-specific cutoff levels (3.5ngml
 1 for ages 55–59 and
4.5ngml
 1 for 63–67) would have resulted in 287 fewer screen-
positive findings (from 1980 to 1693, i.e. from 9.5 to 8.1%) in the
first screening round, that is, slightly lower compared with the
current screening protocol. The number of screen-positive results
would have increased for men in their fifties and decreased for
older men. In the second screening round with 4 years older
subjects, age-specific cutoff levels would have increased the number
of screen-positive findings by 557 compared with the protocol used
in the trial (from 2303 to 2860 i.e. from 12.4 to 15.4%).
DISCUSSION
We report a systematic assessment of specificity in relation to its
several possible determinants in a population-based trial. Our
results show that a reasonably high specificity (above 90%) can be
achieved with the PSA test in prostate cancer screening. Moreover,
specificity decreases only slightly at repeat (incidence) screening,
and this is entirely attributable to ageing of the study subjects.
Overall, specificity of serum PSA as screening test for prostate
cancer was slightly above 90%. A Canadian screening study with a
cutoff of 3ngml
 1 reported 90% specificity (Labrie et al, 1992) and
similar findings were reported from the US (Mettlin et al, 1994). A
volunteer-based study in the US reported specificity of 73%
(Punglia et al, 2005). A meta-analysis estimated specificity of PSA
as 93% at 4.0ngml
 1 (Mistry and Cable, 2003).
Our study population may represent relatively low-risk men, as
the trial is population-based and the subjects are fairly young. Yet,
the incidence of prostate cancer in Finland is rather high in
international comparison, with age-standardised incidence of 84
per 100000 in 2002 (Ferlay et al, 2004). Owing to the representative
study population, our findings are likely to be more applicable to
the general population than those from volunteer-based studies.
Furthermore, we used a consistent definition of specificity, with
systematic evaluation of various factors affecting specificity within
the screening trial.
Specificity was only slightly lower in the second screening round
compared with the first. This was due to participants being older at
the second round. The main factor is probably the strong increase
in prevalence of benign prostatic hyperplasia with age. Introduc-
tion of a new biopsy regimen with increased number of cores may
have also decreased the number of apparent FP screening findings
(if a larger proportion of true-positive findings were detected). In
both rounds, the specificity was higher in the young age groups.
This finding indicates that specificity is likely to decrease at
subsequent screening rounds, as age at screening increases.
Digital rectal examination as an ancillary test among men with
intermediate PSA levels was associated with a lower rate of FP
findings than F/T PSA and hence, slightly higher specificity. The
yield was also lower than with free PSA (2.1% vs 5.2% of men with
PSA 3.0–3.9ngml
 1). This is consistent with the findings from
a Dutch screening trial, where the specificity of DRE was 91%
(Schro ¨der et al, 1998). However, the costs for a DRE are
Table 3 Number of men by screening result and prostate cancer
diagnosis in the second screening round of the Finnish prostate cancer
screening trial
Prostate cancer diagnosis
Screening result Yes No Total
Positive 583
a 1573 2156
b
Negative 45
c 16264 16309
Total 628 17837 18465
b
aScreen-detected prostate cancer.
bA total of 147 screen-positive men failed to
undergo biopsy and were excluded.
cInterval cancer among screen-negative men.
Table 4 The frequency of TN and FP screening findings by age in the
second screening round of the Finnish prostate cancer screening trial
Age TN
a FP
b Specificity (95% CI)
c
59 5700 322 0.947 (0.941–0.952)
63 4464 434 0.911 (0.903–0.919)
67 3426 395 0.897 (0.887–0.906)
71 2719 422 0.866 (0.854–0.878)
Total 16309 1573 0.912 (0.908–0.916)
Abbreviations: CI¼confidence interval; FP¼false positive; TN¼true negative.
aTN:
No. of men with negative screening result (serum PSAo3.0ngml
 1 or PSA 3.0–
3.9ngml
 1 with a negative ancillary examination (benign finding at digital rectal
examination or free/total PSA ratioX0.16)).
bFP: No. of men with positive screening
result (serum PSAo4.0ngml
 1 or PSA 3.0–3.9ngml
 1 with a positive ancillary
examination (suspicious finding at digital rectal examination or free/total PSA
ratioo0.16)) minus number of screen-detected cancers (147 men without biopsy
excluded).
cSpecificity: TN/(TN+FP).
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Figure 1 Specificity by age and screening round.
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ssubstantially higher than determination of F/T PSA in our trial,
where a blood sample is drawn initially and can be used for
determination of both total and free PSA, whereas DRE requires a
separate visit for an urologist.
We estimated the specificity first by assuming that the
proportion of false negatives (cancers among SN men surfacing
during the screening interval) is negligible and can be ignored.
This cross-sectional approach gives a measure that can be called
relative specificity. Longitudinal analysis with correction for false-
negative results (interval cases) is able to take into account the fact
that many men with a negative biopsy do in fact harbour a latent
cancer. Yet, adjustment for this did not materially affect the
results. However, if all men harbouring a focal carcinoma in their
prostates were classified as false negative, the situation would
change dramatically as this has been very common in studies
based on autopsy (Breslow et al, 1977; Kabalin et al, 1989) and
cystoprostatectomy specimens or prostate tissue removed in
transurethral prostatectomy (Montie et al, 1989; Merrill and
Wiggins, 2002). Studies based on natural history models have
estimated that up to 45% of screen-detected cases may be due to
overdiagnosis, that is, cancers that would not have surfaced
clinically during the man’s lifetime if unscreened (Etzioni et al,
2002; Draisma et al, 2003). Thus, latent or minimal disease is very
frequent, and there are good grounds to argue that presence of
malignant histological features alone does not constitute a true
golden standard for clinically significant prostate cancer. This
issue can also been as a problem of FP findings, if overdiagnosed
cases (if identifiable) were to be classified as FP findings. Yet, they
cannot be reliably identified by current means, even if the above
argument was accepted. Both issues, however, emphasise the need
for definition of diagnosis of prostate cancer. We have used the
conventional approach, but taking into the above uncertainties
would have reduced the estimates of specificity.
Not all men with screen-positive result attend diagnostic
examinations, and the results may not be available, if medical
care is sought outside the screening organisation. In our material,
approximately 0.5% of all participants or 5% of screen-positive
men did not undergo biopsy within the trial (in the study
hospitals). In the screening programme, these men are classified as
negatives, that is, no further procedures are undertaken (despite
indications being fulfilled). This is problematic when evaluating a
screening test. In calculation of specificity, these men were
assumed to be true positives and FPs in the same proportion as
those biopsied. Owing to the small number of such cases, this did
not affect our estimate of test specificity.
No consensus has been established as to the optimal use of PSA
and several approaches have been proposed, including age-specific
cutoffs and PSA relative to prostate volume (Gretzer and Partin
2003). Cutoff values even lower than 4ngml
 1 have been proposed
and are being used in some screening projects (Labrie et al, 1992;
Krumholtz et al, 2002; Punglia et al, 2005). In the European
Randomized Study of Screening for Prostate Cancer, ERSPC, a
cutoff level of 3ngml
 1 instead of 4ngml
 1 was associated with
increase in the proportion of test-positive findings from 1.6 to
5.1% (de Koning et al, 2002). Generally, both the proportion of
screening-positive findings and detection rates have been higher in
studies with combined modality screening (e.g., DRE and/or TRUS
in addition to PSA). In our study, a limit of 3ngml
 1 would have
resulted in an increase in FP tests by more than a third. As the
increase in screen-positive findings would be in the low PSA range,
where prostate cancer prevalence is likely to be low and FP results
more common than at higher PSA levels, adopting a lower cutoff
level is likely to reduce specificity.
Age-specific cutoff values have been proposed for PSA in order
to improve specificity of the test among older men (Oesterling
et al, 1993). The rationale is that the prostate volume and
prevalence of benign prostatic hyperplasia increase rapidly after 60
years of age. Use of age-specific cutoff levels would have resulted in
a similar number of screen-positive findings in the first round, but
substantially higher numbers in the second screening round. As no
referrals or biopsy decision were made based on the age-specific
cutoff values, we were not able to directly assess the possible effect
on specificity. It would have resulted in large numbers of screen-
positive men in older age groups and lower numbers in younger
age groups. Because specificity was inversely correlated with age, it
is likely that use of age-specific cutoff values would have resulted
in lower specificity.
There are two approaches for avoiding information bias owing
to PSA-driven biopsy in assessment of validity of the PSA test.
First, it can be argued that everybody should receive the diagnostic
test (prostate biopsy) when evaluating specificity, in order to
completely identify those with disease. In some studies, all men
have been biopsied, regardless of PSA result, which has resulted in
detection of prostate cancer even at low PSA levels (Labrie et al,
1992; Thompson et al, 2004). These studies have also shown
similar specificity for PSA as others (90–94%). Alternatively, the
distortion from ‘affirming the consequent’ can be avoided, when
no test results are followed by diagnostic examination (Walter,
1999). In serum bank studies, the PSA has been determined only
afterwards and therefore it has not affected the diagnosis (Gann
et al, 1995; Hakama et al, 2001). Specificity in this context has been
estimated as 91–94%. Furthermore, cases in the serum bank
studies have been diagnosed mainly before the PSA screening era
and also therefore likely to avoid overdiagnosis.
In comparison with screening for other cancers, our results
indicate similar or slightly lower specificity for PSA in prostate
cancer screening. In mammography screening for breast cancer,
specificity has ranged 82–99%, being commonly slightly above
90% (Elmore et al, 2005). Fairly similar figures (86–100%) have
been reported for the cervical smear in cervix cancer screening
(Nanda et al, 2000; Cervix cancer screening 2005). In faecal occult
blood testing for colorectal cancer, slightly higher specificity (95%
or higher) has been found (Allison et al, 1996; Rozen et al, 2000).
We conclude that screening for prostate cancer based on PSA
determination has acceptable specificity. It should, however, be
further improved if such screening is to be adopted as public
health policy. We do not recommend PSA screening before the
results in terms of mortality from prostate cancer are known.
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